Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful - OTC

Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC); compare to the active ingredient in MiraLAX® Powder for Solution, 17 grams of Bayer HealthCare LLC.

According to Nielsen® syndicated data for the latest 52 weeks' period ending February 22, 2025, the MiraLAX® Powder for Solution, 17 grams (OTC) market achieved annual sales of approximately $555.7 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1406.55 as compared to the previous close of Rs. 1395.40. The total number of shares traded during the day was 9613 in over 840 trades.

The stock hit an intraday high of Rs. 1415.85 and intraday low of 1380.50. The net turnover during the day was Rs. 13454473.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 GlenmarkTherapeutics USA PolyethyleneGlycol3350 PowderforSolution OTC